These results reinforce that our prognostic model is superior to other conventional models based on clinical variables alone in predicting the risk of distant metastasis in HR−/HER2+ breast cancer and provides more accurate prognostic information than traditional clinicopathological factors in this subtype of breast cancer. Here, ERBB2 is linked to breast carcinoma.